You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Long-Term Effect of Antibodies against Infused Alpha-Galactosidase A in Fabry Disease on Plasma and Urinary (lyso)Gb3 Reduction and Treatment Outcome
|
|---|---|
| Published in |
PLOS ONE, October 2012
|
| DOI | 10.1371/journal.pone.0047805 |
| Pubmed ID | |
| Authors |
Saskia M. Rombach, Johannes M. F. G. Aerts, Ben J. H. M. Poorthuis, Johanna E. M. Groener, Wilma Donker-Koopman, Erik Hendriks, Mina Mirzaian, Sijmen Kuiper, Frits A. Wijburg, Carla E. M. Hollak, Gabor E. Linthorst |
| Abstract |
Enzyme replacement therapy (ERT) with alpha-Galactosidase A (aGal A) may cause antibody (AB) formation against aGal A in males with Fabry disease (FD). Anti agalsidase ABs negatively influence globotriaosylceramide (Gb3) reduction. We investigated the impact of agalsidase AB on Gb3 and lysoGb3 and clinical outcome in Fabry patients on ERT. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Netherlands | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 89 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Netherlands | 1 | 1% |
| Unknown | 88 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 16 | 18% |
| Student > Ph. D. Student | 14 | 16% |
| Other | 9 | 10% |
| Student > Master | 7 | 8% |
| Student > Bachelor | 6 | 7% |
| Other | 11 | 12% |
| Unknown | 26 | 29% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 25 | 28% |
| Biochemistry, Genetics and Molecular Biology | 8 | 9% |
| Agricultural and Biological Sciences | 7 | 8% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 4% |
| Chemistry | 3 | 3% |
| Other | 12 | 13% |
| Unknown | 30 | 34% |
Attention Score in Context
This research output has an Altmetric Attention Score of 13. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 30 August 2022.
All research outputs
#2,392,328
of 23,206,358 outputs
Outputs from PLOS ONE
#30,265
of 198,314 outputs
Outputs of similar age
#17,120
of 177,172 outputs
Outputs of similar age from PLOS ONE
#585
of 4,785 outputs
Altmetric has tracked 23,206,358 research outputs across all sources so far. Compared to these this one has done well and is in the 89th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 198,314 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 15.2. This one has done well, scoring higher than 84% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 177,172 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 90% of its contemporaries.
We're also able to compare this research output to 4,785 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 87% of its contemporaries.